Related Experiment Video
Updated: Aug 2, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Prospects for cellular immunotherapy for metastatic melanoma
1Department of Surgery, Duke University Medical Center, Durham, NC.
Abstract:
Systemic therapy for metastatic malignant melanoma has been disappointing. The search for alternate therapeutic methods includes investigation of the interaction between melanoma and the human immune system. A cellular immune response to melanoma has been documented in vitro and in vivo. In most patients with disseminated disease, however, immune T cells fail to eradicate the tumor. While this phenomenon is poorly understood, the occasional occurrence of spontaneous regression provides some indication that the immune response may, in fact, be capable of eradicating established tumor in vivo. Current efforts to augment and to direct the immune response to melanoma include investigation of specific and nonspecific adoptive immunotherapy. Specific therapy includes the generation of tumor-activated specific killer cells from peripheral blood, draining nodes, or metastatic tumor deposits. An increasing understanding of antigen recognition and improved methodology for T-cell culture are contributing toward the application of cellular immunotherapy to patients with melanoma.
Insights
Systemic therapy for metastatic melanoma is challenging. Research explores harnessing the human immune system, specifically cellular immunotherapy, to effectively target and eradicate melanoma tumors.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Metastatic malignant melanoma treatment outcomes remain poor.
- The human immune system shows a cellular response to melanoma, but T cells often fail to eliminate tumors in disseminated disease.
- Spontaneous melanoma regression suggests the immune system's potential to eradicate established tumors.
Purpose of the Study:
- To investigate the interaction between melanoma and the human immune system.
- To explore alternative therapeutic strategies for metastatic melanoma.
- To evaluate the potential of adoptive immunotherapy in combating melanoma.
Main Methods:
- Documenting cellular immune responses to melanoma in vitro and in vivo.
- Investigating specific and nonspecific adoptive immunotherapy approaches.
- Generating tumor-activated specific killer cells from various patient tissue sources.
Main Results:
- A cellular immune response to melanoma is observable.
- T cells frequently fail to eradicate tumors in patients with disseminated melanoma.
- Tumor-activated killer cells can be generated for potential therapeutic application.
Conclusions:
- The human immune system holds potential for eradicating established melanoma tumors.
- Advances in understanding antigen recognition and T-cell culture are crucial for developing effective cellular immunotherapy.
- Adoptive immunotherapy represents a promising avenue for treating patients with melanoma.
